CoChat

Integrating BRAF/MEK inhibitors into combination therapy for melanoma

Open access
Smalley, K S M, Flaherty, K T · 2009 · British Journal of Cancer
Cited by 89

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combinations for future clinical testing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6604891

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 89

Metadata

Authors
Smalley, K. S. M., & Flaherty, K. T.
Venue
British Journal of Cancer
Published
2009-01-20
Volume
100
Issue
3
Pages
431-435
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1972726145
Cited by
89
References
3
FWCI
6.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integrating BRAF/MEK inhibitors into combination therapy for melanoma. https://app.cochat.ai/papers/10.1038/sj.bjc.6604891
The paper
Smalley, K. S. M., & Flaherty, K. T. (2009). Integrating BRAF/MEK inhibitors into combination therapy for melanoma. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604891

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.